Stock Events

Alkermes 

$24.5
30
-$0.31-1.25% Friday 20:00

Statistics

Day High
24.81
Day Low
24.27
52W High
33.71
52W Low
22.01
Volume
1,658,950
Avg. Volume
1,854,919
Mkt Cap
4.15B
P/E Ratio
9.68
Dividend Yield
-
Dividend
-

Earnings

1MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-0.01
0.21
0.42
0.64
Expected EPS
0.59
Actual EPS
0.43

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ALKS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Johnson & Johnson
JNJ
Mkt Cap350.27B
Johnson & Johnson, through its Janssen Pharmaceuticals segment, competes in the pharmaceuticals market, including CNS and mental health treatments, similar to Alkermes' focus areas.
Lilly(Eli) &
LLY
Mkt Cap834.88B
Eli Lilly and Company competes directly with Alkermes in the psychiatric and neurological drug markets, including treatments for depression and schizophrenia.
Pfizer
PFE
Mkt Cap156B
Pfizer Inc. offers products in various therapeutic areas that overlap with Alkermes, including treatments for mental health conditions.
Novartis
NVS
Mkt Cap230.67B
Novartis AG competes in the neuroscience segment, offering medications for neurological conditions, directly competing with Alkermes' portfolio.
Merck &
MRK
Mkt Cap327.95B
Merck & Co., Inc. has a range of pharmaceutical products that compete with Alkermes, especially in the areas of health and well-being, including treatments for conditions affecting the central nervous system.
Bristol-Myers Squibb
BMY
Mkt Cap83.52B
Bristol-Myers Squibb Company has a diverse biopharmaceutical portfolio that includes psychiatric and neurological medications, competing with Alkermes.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap19.05B
Teva Pharmaceutical Industries Limited manufactures generic and specialty medicines, including CNS and neurology products, competing with Alkermes.
Abbvie
ABBV
Mkt Cap297.71B
AbbVie Inc. competes with Alkermes in the neuroscience area, including R&D and marketing of psychiatric and neurological drugs.
Biogen
BIIB
Mkt Cap32.82B
Biogen Inc. focuses on neurology and has a strong presence in the neuroscience field, making it a direct competitor to Alkermes in areas like multiple sclerosis and psychiatric disorders.
AMGEN
AMGN
Mkt Cap163.62B
Amgen Inc. competes in the biopharmaceutical field, focusing on innovative treatments that could overlap with Alkermes' work in CNS disorders.

Analyst Ratings

37.57$Average Price Target
The highest estimate is $50.
From 7 ratings within the last 6 months. This is not an investment recommendation.
Buy
57%
Hold
29%
Sell
14%

About

Health Technology
Biotechnology
Manufacturing
Pharmaceutical Preparation Manufacturing
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Show more...
CEO
Richard F. Pops
Employees
2100
Country
IE
ISIN
IE00B56GVS15
WKN
000A1JKVH

Listings